Analysis of the antitumor immunity activity of α-GalCer according to each organ against the human tumor cell line
Analysis of the antitumor immunity activity of α-GalCer according to each organ against the human tumor cell line
批准号:
18591443
负责人:
FUJI Nobuaki
金额:
$2.39万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2006
资助国家:
日本
项目状态:
已结题
起止时间:
2006 至 2007
中文摘要
点击翻译按钮获取中文摘要
英文摘要
We presented mechanism of the antitumor effect of a-GalCer using a murine spontaneous hepatic metastases model. Therefore this purpose was to investigate antitumor effect of a-GalCer against the human tumor cell line in vitro. At first lymphocytes were divided from human peripheral blood or liver tissue, and a-GalCer was added in them in vitro. Cellular cytotoxicity for the human tumor cell line and a production of cytokine having the anti-tumor activity were measured, and effectors cells were analyzed subsequently. Furthermore, we schemed to investigate whether anti-tumor activity of a-GalCer had organ specificity in a human. The reason was because a-GalCer administration could become a treatment for the metastasis lesion of the cancer patient if this antitumor effect had organ specificity.A study of the antitumor effect of peripheral blood lymphocyte and hepatic lymphocyte: From the patient who underwent abdominal operation peripheral blood and hepatic tissue were obtained, and peripheral blood lymphocytes and hepatic lymphocytes were divided. Human tumor cell line and a-GalCer were added at various kinds of concentration for each lymphocyte, and mixed culture was performed in vitro, and cytotoxic activity by the Cr release examination was measured. However, results having reproducibility could not be obtained in peripheral blood lymphocyte and hepatic lymphocyte. Therefore a further experiment was needed to establish optimal concentration of a-GalCer. Quantity of production of IFN -y or IL-12 could not be evaluated continuously.Effectors analysis of the above lymphocytes: Effectors analysis was started in each lymphocyte for a few examples. However, we did not result in an outcome having reproducibility similarly. A process and an effort to prepare as possible the background of the patient will be most important in future. A scheme and an effort to keep as possible the background of the patient may be most important in future.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Induction of Peptide-Specific Immune Response in Patients with Primaiy Malignant Melanoma of the Esophagus after Immunotherapy Using Dendritic Cells Pulsed with MAGE Peptides.
使用 MAGE 肽脉冲的树突状细胞进行免疫治疗后,对食管原发性恶性黑色素瘤患者诱导肽特异性免疫反应。
DOI:
--
发表时间:
2007
期刊:
Jpn J Clin Oncol 37(2)
影响因子:
--
作者:
[Ueda Y, Itoh T, Fuji N, Yamagishi H (他7名;(4)番目)]
通讯作者:
Yamagishi H (他7名;(4)番目)
Synchronous double cancer of the cystic duct and gallbladder associated with the low junction of the duct
胆囊管和胆囊的同时性双癌,伴有胆管低位交界处
DOI:
--
发表时间:
2007
期刊:
影响因子:
--
作者:
[Itoh T, Fuji N, Taniguchi H, Watanabe T, Kosuga T, Kashimoto K, Naito K]
通讯作者:
Naito K
Intraoperative pathological investigation of recurrent nerve nodal metastasis can guide the decision whether to perform cervical lymph node dissection in thoracic esophageal cancer.
术中对复发神经淋巴结转移的病理学检查可以指导胸段食管癌是否行颈淋巴结清扫术的决定。
DOI:
--
发表时间:
2006
期刊:
Oncol Rep 16 (5)
影响因子:
--
作者:
[Ueda, Y, Fuji, N, Itoh, Yamagishi, H, T, et. al.]
通讯作者:
et. al.
DOI:
10.1093/jjco/hyl136
发表时间:
2007-02
期刊:
Japanese journal of clinical oncology
影响因子:
2.4
作者:
[Y. Ueda;K. Shimizu;Tsuyoshi Itoh;N. Fuji;K. Naito;A. Shiozaki;Yoshiki Yamamoto;Takeshi Shimizu;Arihiro Iwamoto;H. Tamai;H. Yamagishi]
通讯作者:
Y. Ueda;K. Shimizu;Tsuyoshi Itoh;N. Fuji;K. Naito;A. Shiozaki;Yoshiki Yamamoto;Takeshi Shimizu;Arihiro Iwamoto;H. Tamai;H. Yamagishi
A new strategy using autologous dendritic cells and lymphokine-activated killer cells for cancer immunotherapy: efficient maturation of DCs by co-culture with LAK cells in vitro.
使用自体树突状细胞和淋巴因子激活的杀伤细胞进行癌症免疫治疗的新策略:通过与 LAK 细胞体外共培养使 DC 有效成熟。
DOI:
--
发表时间:
2006
期刊:
Oncol Rep 16 (1)
影响因子:
--
作者:
[Yano, Y, Ueda, Y, Itoh, T, Fuji, N, Yamagishi, H, et. al.]
通讯作者:
et. al.
共 17 条
Identification of the CD4 positive helper T cell antigen that aimed at clinical application of specific immunotherapy for gastrointestinal carcinoma
-
批准号:16591341
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.98万
-
财政年份:2004
-
负责人:FUJI Nobuaki
-
依托单位:
国内基金
海外基金
人工合成脂类抗原α-Galcer治疗IDDM的动物实验研究
-
批准号:30070709
-
项目类别:面上项目
-
资助金额:15.0万元
-
批准年份:2000
-
负责人:王福庆
-
依托单位: